According to http://www.firstwordpharma.com/node/992472 , there are (or were as of Jun 2012) more than 25 Rituxan FoB’s in development. No wonder we’re seeing several cancellations already.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”